Clinical Trials
Sep 21, 2026 · 1 min read · 94,493 views
Cue Biopharma's potential Xolair challenger passes Phase 2 chronic hives trial
A
Aiden Brooks
Editorial · Sep 21, 2026
Cue Biopharma's CUE-221 beats Xolair in a Phase 2 chronic hives trial, sending shares up 30% as it eyes a pivotal study
← Previous
UK government committees call for probe into US pharma deal
Next →
FDA faces questions on 'America First' provisions in latest user fee agreement
